First Hawaiian Bank Has $2.18 Million Stock Position in West Pharmaceutical Services, Inc. (NYSE:WST)

First Hawaiian Bank decreased its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 3.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,610 shares of the medical instruments supplier’s stock after selling 220 shares during the period. First Hawaiian Bank’s holdings in West Pharmaceutical Services were worth $2,177,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Fidelis Capital Partners LLC acquired a new stake in shares of West Pharmaceutical Services during the 1st quarter worth approximately $27,000. Quarry LP raised its stake in West Pharmaceutical Services by 155.3% during the fourth quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock worth $34,000 after buying an additional 59 shares during the last quarter. Hazlett Burt & Watson Inc. bought a new position in West Pharmaceutical Services during the first quarter worth $40,000. Northwest Investment Counselors LLC acquired a new stake in West Pharmaceutical Services in the first quarter worth $40,000. Finally, ORG Partners LLC grew its holdings in shares of West Pharmaceutical Services by 820.0% during the first quarter. ORG Partners LLC now owns 138 shares of the medical instruments supplier’s stock valued at $55,000 after buying an additional 123 shares during the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

West Pharmaceutical Services Stock Up 0.4 %

Shares of NYSE WST traded up $1.32 during mid-day trading on Monday, reaching $301.60. 981,158 shares of the company’s stock traded hands, compared to its average volume of 575,223. The stock has a market cap of $21.97 billion, a P/E ratio of 39.61, a PEG ratio of 10.69 and a beta of 1.00. The business has a 50-day simple moving average of $320.53 and a 200 day simple moving average of $354.11. West Pharmaceutical Services, Inc. has a 1-year low of $265.00 and a 1-year high of $415.73. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The company had revenue of $702.10 million during the quarter, compared to the consensus estimate of $729.36 million. During the same period in the prior year, the firm posted $2.11 EPS. The business’s revenue was down 6.9% on a year-over-year basis. On average, analysts expect that West Pharmaceutical Services, Inc. will post 6.44 EPS for the current fiscal year.

Insider Activity at West Pharmaceutical Services

In other news, CEO Eric Mark Green sold 66,000 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total value of $24,198,900.00. Following the completion of the sale, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, SVP Silji Abraham sold 1,800 shares of West Pharmaceutical Services stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total value of $595,404.00. Following the completion of the sale, the senior vice president now directly owns 2,860 shares in the company, valued at $946,030.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Eric Mark Green sold 66,000 shares of West Pharmaceutical Services stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the sale, the chief executive officer now owns 152,908 shares of the company’s stock, valued at $56,063,718.20. The disclosure for this sale can be found here. 0.53% of the stock is owned by insiders.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.